Follow-Ups of Metabolic, Inflammatory and Oxidative Stress Markers, and Brachial–Ankle Pulse Wave Velocity in Middle-Aged Subjects without Metabolic Syndrome

Oh Yoen Kim,1 Jean Kyung Paik,2 Ju Young Lee,3 Sang-Hyun Lee,4 Jong Ho Lee3,5

1Department of Food Science and Nutrition, Dong-A University, Busan, Republic of Korea, 2Department of Food and Nutrition, Eulji University, Gyeonggi-do, Republic of Korea, 3National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, Yonsei University, Seoul, Republic of Korea, 4Department of Family Practice, National Health Insurance Corporation Ilsan Hospital, Goyang-si, Republic of Korea, 5Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul, Republic of Korea

Abstract
This study investigates the association among metabolic risk factors, inflammatory and oxidative stress markers, and brachial–ankle pulse wave velocity (ba-PWV). We conducted a 3-year longitudinal, observational study of 288 middle-aged adults not meeting the criteria for metabolic syndrome (MetS) at the initial screening. We measured metabolic risk factors, inflammatory and oxidative stress markers, and ba-PWV. Within the 3-year study period, 15.6% (45 out of 288) of participants developed MetS. At the 3-year follow-up, patients were categorized as those with MetS (n = 45) and those without MetS (n = 243). Patients with MetS had significantly unfavorable initial measurements of baseline body mass index (BMI), waist circumference (WC), blood pressure (BP), triglyceride (TG), high-density lipoprotein (HDL)-cholesterol, glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR) index, and ba-PWV. After 3 years, participants without MetS showed significant increases in WC, diastolic BP (DBP), total- and low-density lipoprotein (LDL)-cholesterol, malondialdehyde (MDA), oxidized-LDL (ox-LDL), and ba-PWV and a significant decrease in HDL-cholesterol and free fatty acids (FFA). Subjects who developed MetS showed significant increases in BMI, WC, BP, TG, glucose, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), MDA, ox-LDL, and ba-PWV and a significant decrease in HDL-cholesterol. Changes in BMI, WC, BP, TG, HDL-cholesterol, glucose, HOMA-IR index, FFA, C-reactive protein (P = .022), IL-6 (P = .004), leukocyte count (P < .001), MDA (P = .002), ox-LDL (P = .015), and ba-PWV (P = .001) differed significantly between the two groups after adjustment for baseline values. Changes in ba-PWV were positively correlated with the changes in systolic and DBP, total-cholesterol, glucose, leukocyte count, and MDA. The age-related increase in arterial stiffness is greater in the presence of MetS with higher levels of inflammatory and oxidative stress markers.

Keywords: MetS, inflammatory, oxidative stress markers, brachial–ankle pulse wave velocity

INTRODUCTION
Metabolic syndrome (MetS) has been linked to accelerated central arterial aging (i.e., increased arterial stiffness and thickness) (1,2). Some prospective studies show that the progression of arterial stiffness was associated with the changes in MetS risk and was significantly more pronounced in MetS subjects (3,4). A growing body of literature suggests that diverse inflammatory and oxidative stress markers correlate with arterial damage (1,5–7) and, thus, with increased arterial stiffness and thickness (8–11). Inflammatory markers have been reported to be elevated in patients with diabetes mellitus (12), and a proinflammatory state accompanies the presence of altered MetS components. MetS treatment and management programs conventionally focus on patients with the condition; however, careful observation for changes in inflammatory and oxidative stress markers and arterial stiffness is also important for patients at risk for developing MetS.

Therefore, our follow-up study included apparently healthy subjects who do not meet the MetS criteria at baseline, and then after 3 years, subdivided the subjects into non-MetS and MetS, and this study included inflammatory and oxidative stress markers and brachial-ankle pulse wave velocity (ba-PWV) together with metabolic risk factors, and investigated the association of these parameters.
METHODS AND MATERIALS

Study Participants
A total of 288 participants between the ages of 30 and 69 years who visited a health promotion center of the National Health Insurance Corporation of Ilsan Hospital in Korea between October 2006 and October 2007 were enrolled in this study. Participants also completed a personal health and medical history questionnaire, which served as a screening tool. The Institutional Review Board of the National Health Insurance Corporation of Ilsan Hospital approved the study protocol, which was conducted in accordance with the Helsinki Declaration. At the end of the 3-year study, participants were subdivided into groups according to the criteria for MetS (non-MetS and MetS).

MetS was diagnosed if the participants showed at least three of the following components: central obesity (i.e., waist circumference [WC] >90 cm for males and >80 cm for females); high blood pressure (BP) (i.e., systolic BP [SBP] ≥130 mm Hg or diastolic BP [DBP] ≥85 mm Hg); hyperglycemia (i.e., fasting glucose at <70 mg/dL); hypertriglyceridemia (i.e., fasting triglycerides [TGs] >150 mg/dL); and low high-density lipoprotein (HDL)-cholesterol (i.e., HDL-cholesterol <40 mg/dL for males and <50 for females) (13,14).

Anthropometric Parameters, Blood Pressure, Blood Collection, and Energy Intake
Body mass index (BMI) was calculated as body weight in kilograms divided by the square of the height in meters (kg/m²). Waist circumference was measured at the umbilicus with the subjects standing after normal expiration. The SBP and DBP were obtained from the left arms of seated patients with an automatic BP monitor (TM-2654; A&D, Tokyo, Japan) after 20 minutes of rest. After overnight fasting, venous blood samples were collected into plasma and serum, and then stored at −70°C until analysis. Participants were interviewed about their smoking and drinking behaviors. Dietary intake was assessed using a semiquantitative food frequency questionnaire and a 24-hour recall method. Nutrient intake was determined and calculated based on the 3-day food records using the computer-aided nutritional analysis program (CAN-pro 2.0; Korean Nutrition Society, Seoul, Korea). Total energy expenditure (TEE) (kcal/d) was calculated based on the activity patterns of the study participants, such as basal metabolic rate, 24-hour physical activity, and specific dynamic actions of food.

Measurement of Serum Lipid Profiles and Fasting Glucose, Insulin, and Homeostasis and Model Assessment of Insulin Resistance and Free Fatty Acid
Fasting total-cholesterol and TG levels were measured using commercially available kits and a Hitachi 7150 autoanalyzer (Hitachi Ltd., Tokyo, Japan). After precipitation of serum chylomicrons using dextran sulfate magnesium, HDL-cholesterol concentrations in the supernatants were enzymatically measured. For participants with serum TG levels <400 mg/dL, low-density lipoprotein (LDL)-cholesterol levels were estimated directly using the Friedewald formula: LDL-cholesterol = total-cholesterol − (HDL-cholesterol + [TG/5]). Fasting glucose levels were measured by the glucose oxidase method using a Beckman glucose analyzer (Beckman Instruments, Irvine, CA, USA). Insulin levels were measured by a radioimmunoassay using a commercial kit (Immuno Nucleo Corporation, Stillwater, MN, USA). Insulin resistance (IR) was calculated based on the homeostasis model assessment (HOMA) using the following equation: HOMA-IR = (fasting insulin [μIU/mL] × fasting glucose [mmol/L])/22.5. Free fatty acids (FFA) were analyzed with a Hitachi 7150 autoanalyzer.

Measurement of Serum Interleukin-6, Tumor Necrosis Factor-α, High-Sensitivity C-Reactive Protein Levels, and White Blood Cell Counts
Serum interleukin (IL)-6 and tumor necrosis factor (TNF)-α concentrations were measured using Bio-Plex™ reagent kits and a Bio-Plex™ system (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. High-sensitivity C-reactive protein (hs-CRP) levels were measured on an Express Plus™ autoanalyzer (Chiron Diagnostics Co., Walpole, MA, USA) using commercially available hs-CRP-Latex (II) X2 kits (Seiken Laboratories Ltd., Tokyo, Japan). White blood cell (WBC) counts were determined using a hematology analyzer from HORIBA ABX Diagnostic (HORIBA ABX SAS, Parc Euromedicine, France).

Plasma Oxidized-LDL, Malondialdehyde, and ba-PWV Measurements
Plasma oxidized (ox)-LDL levels were measured using an enzyme immunoassay (Mercodia, Uppsala, Sweden). The absorbances of the resulting color reactions were measured at a wavelength of 450 nm using a Wallac Victor² multilabel counter (Perkin Elmer Life Sciences, Turku, Finland). The wavelength correction was set at 540 nm. Plasma malondialdehyde (MDA) concentrations were measured based on the production of thioobarbituric acid-reactive substances (TBARS Assay Kit, Zepto-Metrix Co., Buffalo, NY, USA). Branchial–ankle pulse wave velocities were measured using an automatic waveform analyzer (model VP-1000; Nippon Colin Ltd., Komaki, Japan).

Data Analysis
Statistical analyses were performed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA). The skewed variables were logarithmically transformed for statistical analysis. For descriptive purposes, mean values were presented using untransformed values. Results are expressed as means ± standard error. A two-tailed P value of <.05 was considered statistically significant.
Frequency was tested with the chi-square test. Paired $t$ tests were used to evaluate differences between baseline and 3-year follow-up levels. Differences in the clinical variables between the without MetS and with MetS outcome groups were tested by independent $t$ tests. A general linear model test was applied to adjust for baseline values. Pearson’s correlation coefficients were used to examine the relationships between variables. Multiple logistic regression analyses were also performed.

RESULTS

Clinical Characteristics, Metabolic Risk Factors, Inflammatory and Oxidative Stress Markers, ba-PWV, and Nutrient Intake at Baseline and 3-Year Follow-Up

After 3 years, participants showed a decrease in HDL-cholesterol ($P < .001$), insulin ($P = .039$), and FFA ($P < .001$), and an increase in WC ($P < .001$), DBP ($P = .001$), total-cholesterol ($P = .002$), LDL-cholesterol ($P < .001$), serum TNF-$\alpha$ ($P = .033$), MDA ($P < .001$), ox-LDL ($P < .001$), and ba-PWV ($P < .001$) (Table 1). The estimated total calorie intake was reported at baseline ($2439 \pm 19$ kcal/d) and at the 3-year follow-up ($2428 \pm 18$ kcal/d). No significant differences in macronutrient intake, TEE, smoking, or drinking between the baseline and the 3-year follow-up were noted in whole subjects (data not shown). Additionally, we observed significant decreases in TEE, and significant increases in total calorie intake (TCI)/TEE in the MetS outcome groups, which were not observed in the non-MetS outcome groups (data not shown).

| Table 1. Clinical characteristics, metabolic risk factors, inflammatory and oxidative stress markers, and ba-PWV at baseline and after 3 years |
|------------------|------------------|------------------|------------------|
|                  | Non-MetS ($n = 288$) |               |                 |
|                  | Baseline         | Follow-up        | $P$              |
| Age (y)          | 46.0 ± 0.56      | 49.0 ± 0.57      | <.001            |
| BMI (kg/m$^2$)   | 23.1 ± 0.15      | 23.2 ± 0.15      | .081             |
| Waist (cm)       | 81.9 ± 0.40      | 85.2 ± 0.42      | <.001            |
| SBP (mm Hg)      | 117.0 ± 0.80     | 118.3 ± 0.85     | .084             |
| DBP (mm Hg)      | 76.1 ± 0.62      | 73.6 ± 0.66      | .001             |
| TGs (mg/dL)$^a$  | 100.3 ± 3.39     | 104.6 ± 3.82     | .347             |
| Total-cholesterol (mg/dL)$^a$ | 188.3 ± 1.93 | 193.4 ± 1.91 | .002 |
| HDL-cholesterol (mg/dL)$^a$ | 55.3 ± 0.87 | 51.9 ± 0.84 | <.001 |
| LDL-cholesterol (mg/dL)$^a$ | 113.3 ± 1.85 | 121.2 ± 1.71 | <.001 |
| Glucose (mg/dL)$^a$ | 90.6 ± 0.59 | 92.3 ± 0.56 | .006 |
| Insulin (IU/mL)$^a$ | 8.40 ± 0.20 | 8.05 ± 0.23 | .039 |
| $^b$HOMA-IR$^a$ | 1.89 ± 0.05      | 1.85 ± 0.06      | .196             |
| FFA (Eq/L)$^a$   | 513.5 ± 14.5     | 437.2 ± 12.3     | <.001            |
| hs-CRP (mg/dL)$^a$ | 1.17 ± 0.14 | 1.12 ± 0.13 | .943 |
| Serum IL-6 (pg/mL)$^a$ | 3.59 ± 0.19 | 3.34 ± 0.14 | .964 |
| Serum TNF-$\alpha$ (pg/mL)$^a$ | 8.75 ± 0.48 | 9.36 ± 0.48 | .033 |
| WBCs ($\times 10^9$/L)$^a$ | 5.45 ± 0.10 | 5.35 ± 0.09 | .538 |
| $^b$ba-PWV (cm/s)$^a$ | 1293.6 ± 10.9 | 1334.2 ± 11.4 | <.001 |
| MDA (nmol/mL)$^b$ | 7.95 ± 0.16 | 11.1 ± 0.16 | <.001 |
| ox-LDL (U/L)$^b$ | 33.2 ± 0.67 | 44.1 ± 0.66 | <.001 |

$^a$Means $\pm$ SE tested by logarithmic transformation, $P$ values derived from paired $t$ test.

$^b$HOMA-IR = (fasting insulin (\muIU/mL) $\times$ fasting glucose (mmol/L))/22.5.

$^b$ba-PWV = brachial–ankle pulse wave velocity.

Abbreviations: BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TGs – triglycerides; FFA – free fatty acids; WBCs – white blood cells; MDA – malondialdehyde; ox-LDL – oxidized-LDL.

Metabolic Risk Factors and Lipid Profiles According to MetS Outcome at 3 Years

Within a 3-year interval, 15.6% (45 out of 288) of the participants met the criteria for MetS. At the 3-year follow-up, participants were divided into two groups according to MetS outcome: those who developed MetS ($n = 45$) and those who did not develop MetS ($n = 243$). At baseline, participants who later developed MetS showed significantly unfavorable measurements for baseline BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, and HOMA-IR index (Table 2). After 3 years, participants who did not develop MetS showed a significant increase in WC, DBP, total- and LDL-cholesterol, and a significant decrease in HDL-cholesterol and FFA. Participants who developed MetS showed a significant increase in BMI, WC, BP, TG, and glucose, and a significant decrease in HDL-cholesterol. Changes in BMI, WC, BP, TG, HDL-cholesterol, glucose, HOMA-IR index, and FFA were significantly different between the non-MetS and MetS groups after adjustment for baseline values. At the 3-year follow-up, participants who developed MetS had significantly unfavorable measurements for BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, HOMA-IR index, and FFA (Table 2).

Inflammatory and Oxidative Stress Markers and ba-PWV According to MetS Outcome at 3 Years

At baseline, participants who later developed MetS had significantly higher ba-PWV than those who did not develop MetS ($P < .001$) (Table 3). However, there were no significant differences in inflammatory and oxidative stress markers between the non-MetS and MetS groups at baseline. After 3 years, participants without MetS showed a significant increase in MDA ($P < .001$), ox-LDL ($P < .001$), and ba-PWV ($P < .001$). Participants with MetS showed a significant increase in IL-6 ($P = .011$), TNF-$\alpha$ ($P = .017$), MDA ($P < .001$), ox-LDL ($P < .001$), and ba-PWV ($P < .001$). Changes in hs-CRP ($P = .022$), IL-6 ($P = .004$), leukocyte count ($P < .001$), MDA ($P = .002$), ox-LDL ($P = .015$), and ba-PWV ($P = .001$) were significantly different between the non-MetS and MetS groups after adjustment for baseline values. Additionally, changes in ba-PWV were significantly different between the two groups after further adjustment for baseline ba-PWV, SBP, DBP, and heart rate ($P = .002$). At the 3-year follow-up,
Table 2. Clinical characteristics, metabolic risk factors, and lipid profiles according to the MetS outcome at 3 years

|                      | Without MetS outcome (n = 243) | With MetS outcome (n = 45) | \( P^b \) | \( P^c \) | \( P^d \) |
|----------------------|--------------------------------|---------------------------|---------|---------|---------|
| **Baseline: non-MetS (n = 288)** |                                |                           |         |         |         |
| Male/female, n (%)   | 130 (53.5)/113 (46.5)          | 30 (66.7)/15 (33.3)       | .102    |         |         |
| Cigarette smoker, n (%) | 61 (25.1)                  | 16 (35.6)                  | .146    |         |         |
| Alcohol drinker, n (%) | 166 (68.3)               | 31 (68.9)                  | .939    |         |         |
| BMI (kg/m²)          |                                |                           |         |         |         |
| Baseline             | 22.8 ± 0.16                   | .521                      | .006    | <.001   |         |
| Follow-up            | 22.8 ± 0.16                   |                           |         |         |         |
| Change               | 0.05 ± 0.07                   | 0.49 ± 0.17               | .013    | <.001   |         |
| WC (cm)              |                                |                           |         |         |         |
| Baseline             | 81.1 ± 0.42                   | <.001                     |         | <.001   | <.001   |
| Follow-up            | 84.1 ± 0.44                   | 91.4 ± 0.81               | <.001   |         |         |
| Change               | 2.96 ± 0.37                   | 5.54 ± 0.80               | .006    | <.001   |         |
| SBP (mm Hg)          |                                |                           |         |         |         |
| Baseline             | 115.8 ± 0.86                  | .942                      | .001    | <.001   | <.001   |
| Follow-up            | 115.8 ± 0.83                  | 131.7 ± 2.13              | <.001   |         | <.001   |
| Change               | 0.06 ± 0.79                   | 8.27 ± 2.27               | .001    |         |         |
| DBP (mm Hg)          |                                |                           |         |         |         |
| Baseline             | 70.5 ± 0.67                   | .036                      | <.001   | <.001   |         |
| Follow-up            | 71.9 ± 0.69                   | 82.8 ± 1.43               | <.001   |         |         |
| Change               | 1.37 ± 0.65                   | 5.42 ± 1.36               | .013    | <.001   |         |
| TGs (mg/dL)          |                                |                           |         |         |         |
| Baseline             | 93.0 ± 3.10                   | .589                      | <.001   | <.001   |         |
| Follow-up            | 91.9 ± 3.37                   | 173.1 ± 12.0              | <.001   |         |         |
| Change               | −1.05 ± 3.03                  | 32.9 ± 9.25               | .001    | <.001   |         |
| Total-cholesterol (mg/dL) |                          |                           |         |         |         |
| Baseline             | 187.5 ± 2.04                  | .001                      |         | .446    | .500    |
| Follow-up            | 193.3 ± 2.06                  | 194.0 ± 5.04              | .926    |         |         |
| Change               | 5.81 ± 1.76                   | 1.42 ± 5.10               | .345    |         |         |
| HDL-cholesterol (mg/dL) |                          |                           |         |         |         |
| Baseline             | 56.5 ± 0.96                   | .002                      | <.001   | .001    | <.001   |
| Follow-up            | 53.8 ± 0.92                   | 41.5 ± 1.26               | <.001   |         |         |
| Change               | −2.70 ± 0.84                  | −7.13 ± 1.40              | .008    | <.001   |         |
| LDL-cholesterol (mg/dL) |                          |                           |         |         |         |
| Baseline             | 112.4 ± 1.90                  | <.001                     |         | .688    | .157    |
| Follow-up            | 121.4 ± 1.84                  | 120.0 ± 4.63              | .752    |         |         |
| Change               | 8.91 ± 1.77                   | 1.87 ± 5.36               | .141    |         |         |
| Glucose (mg/dL)      |                                |                           |         |         |         |
| Baseline             | 90.0 ± 0.62                   | .093                      | .041    |         |         |
| Follow-up            | 91.1 ± 0.57                   | 98.4 ± 1.52               | <.001   |         |         |
| Change               | 1.12 ± 0.66                   | 4.84 ± 1.31               | .023    | <.001   |         |
| Insulin (IU/mL)      |                                |                           |         |         |         |
| Baseline             | 8.15 ± 0.21                   | .055                      | .443    | .008    |         |
| Follow-up            | 7.78 ± 0.23                   | 9.52 ± 0.70               | .006    |         |         |
| Change               | −0.37 ± 0.26                  | −0.22 ± 0.59              | .819    | .093    |         |
| HOMA-IR              |                                |                           |         |         |         |
| Baseline             | 1.81 ± 0.05                   | .160                      | .870    | .002    |         |
| Follow-up            | 1.76 ± 0.06                   | 2.32 ± 0.19               | <.001   |         |         |
| Change               | −0.05 ± 0.06                  | 0.04 ± 0.15               | .587    | .032    |         |
| FFA (Eq/L)           |                                |                           |         |         |         |
| Baseline             | 520.8 ± 16.2                  | <.001                     | .238    | .431    |         |
| Follow-up            | 427.4 ± 13.5                  | 500.0 ± 27.2              | .001    |         |         |
| Change               | −93.5 ± 18.6                  | 33.1 ± 25.6               | <.001   | .004    |         |

*Means ± SE tested by logarithmic transformation.

*P values derived from paired t test.

*P values derived from independent t test.

*P values derived after adjustment for baseline value.

Abbreviations: BMI – body mass index; WC – waist circumference; SBP – systolic blood pressure; DBP – diastolic blood pressure; TGs – triglycerides; FFA – free fatty acids.

Participants with MetS had significantly unfavorable inflammatory and oxidative stress measurements for IL-6 (\( P = .002 \)), leukocyte count (\( P < .001 \)), MDA (\( P = .004 \)), and ba-PWV (\( P < .001 \)).

Relationship between Changes in ba-PWV and Changes in Metabolic, Inflammatory, and Oxidative Stress Markers

Changes in ba-PWV were positively correlated with changes in SBP (\( r = 0.287, P < .001 \)), DBP (\( r = 0.155, \))
Table 3. Inflammatory and oxidative stress markers and ba-PWV according to MetS outcome at 3 years

|                      | MetS outcome (n = 243) | \( P^a \) | MetS outcome (n = 45) | \( P^b \) | \( P^c \) | \( P^d \) |
|----------------------|------------------------|----------|-----------------------|----------|----------|----------|
| hs-CRP (mg/dL)       |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 1.23 ± 0.16            | .733     | 0.87 ± 0.08           | .442     | .153     |          |
| Follow-up\(^a\)      | 1.06 ± 0.14            |          | 1.44 ± 0.35           | .061     |          |          |
| Change                | −0.16 ± 0.21           |          | 0.57 ± 0.36           | .147     | .022     |          |
| Serum IL-6 (pg/mL)   |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 3.66 ± 0.22            | .270     | 3.24 ± 0.33           | .011     | .483     |          |
| Follow-up\(^a\)      | 3.14 ± 0.14            |          | 4.35 ± 0.47           | .002     |          |          |
| Change                | −0.53 ± 0.26           |          | 1.11 ± 0.49           | .009     | .004     |          |
| Serum TNF-α (pg/mL)  |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 8.94 ± 0.55            | .147     | 7.77 ± 0.77           | .017     | .743     |          |
| Follow-up\(^a\)      | 9.33 ± 0.56            |          | 9.49 ± 0.64           | .196     |          |          |
| Change                | 0.40 ± 0.75            |          | 1.73 ± 1.01           | .451     | .493     |          |
| WBCs (×10^3/L)       |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 5.41 ± 0.11            | .143     | 5.67 ± 0.22           | .137     | .235     | <.001    |
| Follow-up\(^a\)      | 5.21 ± 0.09            |          | 6.13 ± 0.27           | <.001    |          |          |
| Change                | −0.20 ± 0.11           |          | 0.46 ± 0.33           | .027     | <.001    |          |
| MDA (nmol/mL)        |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 9.69 ± 0.18            | <.001    | 10.1 ± 0.39           | <.001    | .327     |          |
| Follow-up\(^a\)      | 10.9 ± 0.18            |          | 12.2 ± 0.41           | .004     |          |          |
| Change                | 1.21 ± 0.15            |          | 2.15 ± 0.41           | .018     | .002     |          |
| ox-LDL (U/L)         |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 33.3 ± 0.76            | <.001    | 32.7 ± 1.34           | <.001    | .910     |          |
| Follow-up\(^a\)      | 43.6 ± 0.67            |          | 46.9 ± 2.04           | .249     |          |          |
| Change                | 10.2 ± 0.70            |          | 14.3 ± 1.97           | .061     | .015     |          |
| ba-PWV (cm/s)        |                        |          |                       |          |          |          |
| Baseline\(^a\)       | 1274.0 ± 11.1          | <.001    | 1396.7 ± 31.8         | <.001    | <.001    |          |
| Follow-up\(^a\)      | 1308.4 ± 11.6          |          | 1469.1 ± 29.3         | <.001    |          |          |
| Change                | 34.5 ± 7.35            |          | 72.4 ± 19.7           | .046     | .001     |          |

\(^a\)Mean ± SE tested by logarithmic transformation.
\(^b\)P values derived from paired \( t \) test.
\(^c\)P values derived from independent \( t \) test.
\(^d\)P values derived after adjustment for baseline value.

Abbreviations: hs-CRP – high-sensitivity C-reactive protein; IL-6 – interleukin-6; TNF-α – tumor necrosis factor-α; WBCs – white blood cells; MDA – malondialdehyde; ox-LDL – oxidized-LDL; ba-PWV – branchial–ankle pulse wave velocity.

\( P = .010 \), total-cholesterol \(( r = 0.137, P = .024 \)\), glucose \(( r = 0.152, P = .012 \)\), leukocyte count \(( r = 0.121, P = .046 \)\), and MDA \(( r = 0.131, P = .046 \)\). Changes in leukocyte count were positively correlated with changes in BMI \(( r = 0.159, P = .007 \)\), WC \(( r = 0.135, P = .023 \)\), CRP \(( r = 0.299, P < .001 \)\), and IL-6 \(( r = 0.314, P < .001 \)\). Changes in MDA were positively correlated with changes in ox-LDL \(( r = 0.139, P = .039 \)\), DBP \(( r = 0.137, P = .033 \)\), and total-cholesterol \(( r = 0.176, P = .006 \)\). Furthermore, changes in IL-6 were positively correlated with changes in CRP \(( r = 0.388, P < .001 \)\).

DISCUSSION

Major strengths of this report include the longitudinal, observational study of middle-aged individuals not meeting the MetS criteria, the inclusion of ba-PWV (a marker of arterial stiffness) (15), and the inclusion of several inflammatory and oxidative stress markers and MetS components. The results of this study suggested that age-associated changes in ba-PWV and inflammatory and oxidative stress markers differ between individuals with and without MetS outcomes. Additionally, the age-related increase in ba-PWV was associated with changes in inflammatory and oxidative stress markers. The age-related increase in arterial stiffness was greater in patients who developed MetS and showed higher levels of inflammatory and oxidative stress markers.

Pulse wave velocity is an established index of arterial stiffness (16), and ba-PWV shows characteristics similar to those of central aortic PWV (17). Arterial stiffness, one of the most significant manifestations of vascular aging (18,19), can increase SBP (20,21), and increases with age, even in healthy individuals without clinical cardiovascular disease (CVD) (22). The underlying mechanisms responsible for arterial stiffness remain unknown; however, oxidative stress, such as the age-related increase in ox-LDL and MDA in middle-aged subjects, could play an important role given that there were positive correlations between changes in ba-PWV and MDA in middle-aged subjects, could play an important role given that there were positive correlations between changes in ba-PWV and MDA in middle-aged subjects.

Clinical and Experimental Hypertension
and SBP of studied patients were independently associated with ba-PWV. Recently, Brinkley et al. (11) also suggested that oxidative stress, including ox-LDL, may be related to the pathogenesis of arterial stiffness, independent of other CVD risk factors.

The presence of CVD risk factors, including obesity, has been shown to accelerate the vascular changes that result in arterial stiffening (22). In this study, age-related changes in BMI, ba-PWV, and inflammatory and oxidative stress markers were greater in individuals who developed MetS than in those who did not. Increased evidence suggests that obesity and being overweight constitute low-grade inflammatory states (24,25). A chronic inflammatory response might increase the blood concentration of acute-phase reactants, including leukocytes (25). Thus, detecting a high leukocyte count or a change in the count has been linked to predicting specific diseases, such as MetS (26), subclinical atherosclerosis (25), and CVD (27), as well as all-cause mortality (28).

Meanwhile, cytokines, such as IL-6 (a potent leukocyte differentiation factor), have been associated with IR (29). Interleukin-6, which is produced by immune cells and adipose tissue (30), increases hepatic synthesis of CRP (31). In this study, changes in IL-6 were associated with changes in leukocyte count and hs-CRP. In addition, changes in leukocyte count were positively correlated with changes in BMI and ba-PWV. This result supports the previous suggestion of a possible synergistic effect between MetS and inflammation on the arterial wall (1).

Within 3 years, a considerable number (15.6%; 45 out of 288) of the middle-aged participants of this study fulfilled the criteria for MetS. The incidence of MetS in our middle-aged study population was as high as reported in a survey for Korean middle-aged adults (2005 Korea National Health and Nutrition Examination Survey Report III). Participants with MetS outcomes had significantly unfavorable initial measurements, including baseline BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, HOMA-IR index, and ba-PWV. These results are consistent with a previous finding of a significant correlation between the baseline MetS component count and MetS development (14). In fact, Lin et al. (14) showed that middle-aged adults having one or two MetS components had a 2.8-fold and 7.3-fold increased risk for developing MetS within 5 years, respectively, versus adults having no MetS components.

Additionally in our study, significant decreases in TEE and significant increases in TCI/TEE were observed in the MetS outcome groups after the 3-year follow-up, but which were not observed in the non-MetS outcome groups. Our result is partly in accordance with the work of Esmaillzadeh and Azadbakht (32), which shows that higher dietary energy density was significantly associated with a greater risk of MetS and most of its components. It may suggest that usual lifestyle is closely associated with the risk of MetS and important in the prevention of MetS.

In conclusion, this study showed that the simultaneous occurrence of MetS and higher proinflammatory and oxidative stress markers increase the likelihood for greater age-related increases in arterial stiffness. Therefore, lifestyle modifications, such as caloric restriction and exercise, are recommended to the middle-aged individuals at risk for MetS criteria as an efficacious therapeutic intervention for preventing MetS and the progression of arterial stiffness.

Declaration of interest: None of the authors have conflicts of interest in relation to the materials presented in this article.

This work was supported by the Mid-Career Researcher Program through National Research Foundation, Ministry of Education, Science and Technology (2012-0005604, M10642120002-06N4212-00210, 2012M3A9C4048762 and 2012-0001851), Republic of Korea.

REFERENCES

[1] Scuteri A, Orru M, Morrell C, et al. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA study. Atherosclerosis 2011; 215:499–464.
[2] Scuteri A, Najjar SS, Muller DC, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004; 43:1388–1395.
[3] Tomiyama H, Hirayama Y, Hashimoto H, et al. The effects of changes in the metabolic syndrome detection status on arterial stiffening: a prospective study. Hypertens Res 2006; 29(9): 673–678.
[4] Safar ME, Thomas F, Blacher J, et al. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 2006; 47(1):72–75.
[5] Grundy SM. Inflammation, hypertention, and the metabolic syndrome. J Am Med Assoc 2003; 290:3000–3002.
[6] Kampus P, Muda P, Kals J, et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension. Int J Cardiol 2006; 112:46–51.
[7] Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 2009; 69:594–601.
[8] Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189:47–60.
[9] Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 2004; 344:1–12.
[10] Ridker PM, Buring JE, Shih J, Matias M, Hennetkens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731–733.
[11] Brinkley TE, Nicklas BJ, Kanaya AM, et al. Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: the health, aging, and body composition study. Hypertension 2009; 53:846–852.
[12] Barzilay JL, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes 2001; 50:2384–2389.
[13] Hsu PF, Chuang SY, Cheng HM, Tsai ST, Chou P, Chen CH. Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: a community-based study. Diabetes Res Clin Pract 2008; 79:461–467.
[14] Lin YC, Hsiao TJ, Chen PC. Persistent rotating shift-work exposure accelerates development of metabolic syndrome among middle-aged female employees: a five-year follow-up. Chronobiol Int 2009; 26:740–755.
[15] Hung CS, Lin JW, Hsu CN, et al. Using brachial-ankle pulse wave velocity to associate arterial stiffness with cardiovascular risks. Nutr Metab Cardiovasc Dis 2009; 19:241–246.

[16] Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010; 74:24–33.

[17] Tsuchikura S, Shoji T, Kimoto E, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17:658–665.

[18] Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107:139–146.

[19] Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107:490–497.

[20] Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005; 66L:307–317.

[21] O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007; 50:1–13.

[22] Zieman SJ, Melenevsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:932–943.

[23] Tso TK, Huang WN, Huang HY, Chang CK. Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus 2005; 14(11):878–883.

[24] Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83:847–850.

[25] Sekitani Y, Hayashida N, Kadota K, et al. White blood cell count and cardiovascular biomarkers of atherosclerosis. Biomarkers 2010; 15:454–460.

[26] Lao XQ, Neil Thomas G, Jiang C, et al. White blood cell count and the metabolic syndrome in older Chinese: the Guangzhou Biobank cohort study. Atherosclerosis 2008; 201:418–424.

[27] Li C, Engström G, Hedblad B. Leukocyte count is associated with incidence of coronary events, but not with stroke: a prospective cohort study. Atherosclerosis 2010; 209:545–550.

[28] Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. J Am Med Assoc 1985; 254:1932–1937.

[29] Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86:1154–1159.

[30] Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82:4196–4200.

[31] Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Interrelationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 2007; 5:1637–1643.

[32] Esmaillzadeh A, Azadbakht L. Dietary energy density and the metabolic syndrome among Iranian women. Eur J Clin Nutr 2011; 65(5):598–605.